Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity.
Verduin M, Hoosemans L, Vanmechelen M, van Heumen M, Piepers JAF, Astuti G, Ackermans L, Schijns OEMG, Kampen KR, Tjan-Heijnen VCG, de Barbanson BA, Postma AA, Eekers DBP, Broen MPG, Beckervordersandforth J, Staňková K, de Smet F, Rich J, Hubert CG, Gimenez G, Chatterjee A, Hoeben A, Vooijs MA.
Verduin M, et al. Among authors: rich j.
Neurooncol Adv. 2023 Nov 25;5(1):vdad152. doi: 10.1093/noajnl/vdad152. eCollection 2023 Jan-Dec.
Neurooncol Adv. 2023.
PMID: 38130902
Free PMC article.